The Daily Brief

October 31, 2026

Federal marijuana rescheduling is colliding with tax law chaos, forcing thousands of cannabis businesses into a holding pattern while politicians pursue legalization campaigns and the DEA hands out the first federal registrations.

The Drug Enforcement Administration has approved more than 900 medical marijuana dispensaries across Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia to operate under federal law—the first major wave of registrations under President Trump's April rescheduling order that moved state-licensed medical cannabis from Schedule I to Schedule III. For the remaining nearly 7,000 businesses still in the application queue, the DEA issued a hard deadline: establish compliant supply chains by November 29. Manufacturers and distributors face additional hurdles, including facility inspections and quota determinations, meaning the path to federal approval remains lengthy and complex. Money The rescheduling process has already generated approximately $12.3 million in DEA application fees from nearly 7,000 business applications, with manufacturers accounting for the largest share of revenue despite dispensaries representing the majority of applications.

Yet the biggest immediate problem isn't registration—it's taxes. Missouri cannabis businesses have been waiting since April for federal guidance on how rescheduling changes Section 280E, the tax rule that has historically prevented cannabis businesses from deducting ordinary expenses like employee salaries and rent, resulting in effective tax rates as high as 80 percent compared to the standard 21 percent corporate rate. The April order moved medical marijuana to Schedule III but left recreational in Schedule I, creating an impossible calculus for the many states—including Missouri, California and others—where businesses operate both under a single license. The Treasury Department and IRS listed Section 280E guidance as a priority for the next fiscal year running through September 2027, but that priority sits among more than 100 other tasks. California has already seen 95 businesses split their combined medical-recreational licenses into separate entities to position themselves for potential federal registration and tax relief, with regulators estimating roughly 1,600 licensed businesses could qualify under proposed permanent regulations. Context Without federal tax guidance, businesses operating in mixed medical-recreational states face a fundamental uncertainty: how much of their spending they can legally deduct, making long-term financial planning nearly impossible.

On the political side, Democratic Kansas gubernatorial candidate Senator Cindy Holscher has made legal medical and recreational marijuana central to her campaign platform, capitalizing on documented public support for legalization in the state. A new package of proposed regulations in Maryland would allow dispensaries to use secured "sniff jar" displays so customers can see and smell products before purchasing—a retail innovation reflecting the normalizing shift in how states treat cannabis sales. Massachusetts lawmakers advanced $6 million in funding for marijuana regulatory reforms, including restructuring the Cannabis Control Commission and implementing social consumption licensing procedures, while a provision would make it easier for military veterans to obtain medical marijuana cards by accepting Veterans Affairs documentation instead of requiring standard medical certification.

Meanwhile, revenue pressures are forcing fiscal reckoning in states with existing legal markets. Michigan lawmakers proposed suspending the state's 24 percent wholesale cannabis tax for one year after the tax trailed revenue projections, signaling that cannabis taxation—once seen as a cash cow—requires ongoing calibration as markets mature. Money New Jersey's recreational marijuana market generated $117.47 million in September sales, up 23.1 percent year-over-year, with substantial growth among microbusinesses, social equity operators and minority-owned businesses, demonstrating sustained consumer demand even as federal policy remains in transition.

The landscape reflects a fundamental split: federal rescheduling has opened pathways for medical registration and begun dismantling decades of blanket prohibition, yet the machinery of tax law, supply chain compliance and regulatory guidance remains incomplete. Businesses waiting for November 29 deadlines and IRS clarity are operating in a narrowing window where political momentum for legalization is building at the state level even as federal bureaucracy struggles to keep pace with the legal categories the government itself created.

October 31, 2026

Khalifa Kush's decade-long survival stands as a stark contrast to the graveyard of celebrity cannabis brands that flooded the market and collapsed. While competitors from Snoop Dogg to Wiz Khalifa's peers took massive upfront payments from big capital firms—only to watch those deals implode under regulatory pressure, debt, and inconsistent product quality—Khalifa Kush stayed lean, privately controlled, and culturally coherent. The brand's co-founder Tim Hunkele attributed much of that resilience to a brutal early lesson: when Supreme Cannabis attempted to expand Khalifa Kush into Canada after legalization in 2018, Health Canada effectively blocked the partnership almost immediately, while simultaneously allowing counterfeit products bearing Wiz's name to flood the market anyway. That regulatory whiplash forced the company to reject the growth-at-all-costs playbook and build something sustainable instead.

Money The DEA has now granted federal registrations to more than 900 medical marijuana dispensaries across Alabama, Florida, Mississippi, South Dakota, Texas, Virginia, and West Virginia—the first major wave of approvals under President Trump's rescheduling order that moved state-regulated medical cannabis from Schedule I to Schedule III in April. Attorney General Todd Blanche emphasized that these registrations expand patient access to cannabis for chronic pain while maintaining federal oversight, though the DOJ made clear that state licensure alone does not automatically grant federal protection; applicants must independently satisfy DEA requirements including security measures, inventory controls, and recordkeeping standards. The initial batch covers dispensaries that submitted applications during the 60-day expedited window, with the agency now reviewing registrations for manufacturers, distributors, and testing labs—nearly 7,000 medical marijuana businesses have already applied for federal protections across the rescheduling framework.

Florida's medical marijuana market continues to set new benchmarks. Patients have purchased more than 180 million grams of smokable flower in 2026 alone, while the registered patient population reached 943,844 qualified cardholders as of October 30—within 6,150 patients of the 950,000 mark. Notable In a single week, patients acquired 4.27 million grams of flower and more than 429 million milligrams of THC across all products, demonstrating sustained clinical demand. Trulieve maintains its dominant position with 33.6% of all flower dispensed statewide, while MÜV, Curaleaf, and Ayr Cannabis round out the top operators; the state has also approved two new dispensary locations, bringing the total to 786.

Money Montana's cannabis market has undergone a structural shift: concentrates have surpassed flower as the state's largest product category by revenue for the first time, generating $128.4 million during the most recent 12-month reporting period—a 10.2% increase year-over-year. Flower sales, which previously dominated, declined 6.1% to $126.8 million, marking a reversal from the prior year when flower led with $135.1 million. Pre-rolled products showed even stronger growth at 16.1%, rising from $31 million to $35.9 million, while overall cannabis sales grew 2.5% to $330.4 million across the four major categories. However, average retail prices continued falling across the board: flower prices dropped 3.7% from $5.34 to $5.14 per gram, while concentrate prices fell 5.9% from $30.61 to $28.81 per gram.

Curaleaf announced the graduation of its inaugural New York incubator program cohort—a free six-module training designed in partnership with Terp Bros to equip independent dispensary owners with hands-on instruction in compliance, operations, marketing, and finance. The company also announced plans to expand the incubator into additional cohorts and states, signaling a multistate rollout of the business development initiative aimed at supporting smaller operators navigating regulatory requirements and competitive pressures in newly legal markets.

Context These developments reflect a broader normalization of cannabis: federal registrations now extend to nearly 1,000 dispensaries across seven states, Florida's patient population approaches one million, and even product category preferences are shifting as concentrates gain market share. Meanwhile, states that have legalized cannabis continue generating substantial tax revenue, creating widening disparities with states that maintain prohibition.

October 31, 2026

Federal hemp regulations are hurtling toward a critical deadline, with December 11 now marking the point at which intoxicating hemp products face de facto prohibition across most of America. Congress delayed the original November 12 effective date by one month after passing the 2027 Continuing Appropriations and Extensions Act in September, but the clock is ticking for businesses like Moon Flower Hemp in Buckhannon, West Virginia, which has served as a downtown anchor for three and a half years selling traditional THC and CBD products to adults across the region. The November 12 deadline does remain in effect for synthetic cannabinoids, meaning delta-8 and delta-10 products synthesized in labs will become illegal within days, regardless of Congress's December 11 extension for naturally occurring hemp strains.

Money The financial stakes are enormous and already visible in markets where hemp bans have taken effect. Ohio's licensed recreational marijuana dispensaries saw weekly sales jump 20.1%—from $19.6 million to $23.6 million per week—following the state's March hemp ban, generating $613.4 million in purchases between April and October compared to $196.5 million during the same period the previous year. That surge coincides with the removal of intoxicating hemp products from gas stations, convenience stores, and specialty retailers, effectively channeling customers toward regulated marijuana dispensaries. The pattern reveals what happens when one legal market is restricted: consumers don't disappear; they migrate to the regulated alternative, and licensed operators capture the revenue.

Behind the legislative push for hemp restrictions lies a documented effort by major alcohol companies to shape federal policy. Politico obtained emails showing lobbyists for Anheuser-Busch, Molson Coors, and Diageo urged state attorneys general to pressure Congress against extending the hemp deadline. In July, a lobbyist working for Anheuser-Busch emailed North Dakota's attorney general, warning of "fringe U.S. Senators" attempting to extend the loophole. That August, North Dakota's attorney general joined 34 other state officials in a bipartisan letter opposing any delay to the hemp ban. Context Alcohol kills approximately 95,000 Americans annually, while cannabis has zero recorded overdose deaths in human history—yet the industry most associated with preventable deaths is actively lobbying to restrict a legal product with no comparable mortality risk.

Notable Scientists at Sam Houston State University developed a new forensic testing method capable of distinguishing marijuana from hemp in four minutes with 94% accuracy, using copper-based compounds and mass spectrometry to identify delta-9 THC without interference from CBD. The technique, published October 27 in Analytical Methods, correctly classified 34 of 36 authentic cannabis samples. The research was funded by the U.S. Department of Justice's National Institute of Justice and addresses a persistent challenge facing laboratories adapting to federal hemp regulations that rely on a 0.3% THC threshold. Faster, more reliable testing infrastructure could help enforcement agencies if regulations tighten, while also reducing lab backlogs and improving the accuracy of cannabis classification across the supply chain.

Congress is simultaneously moving to restrict hemp imports and protect domestic cultivators. Rep. Val Hoyle (D-OR) introduced the Protecting American Hemp Farmers Act on October 29, proposing a 50% tariff on hemp and cannabinoid products imported from China and mandatory testing requirements for all imported cannabinoid products regardless of origin. The bill would establish new tariff classifications for cannabinoid isolates, distillates, and synthetically altered cannabinoids, while requiring U.S. Customs and Border Protection and the FDA to coordinate testing for heavy metals, mold, pesticides, microbial contamination, and residual solvents. CBP would also publish annual reports tracking imports by source country, product classification, and testing results—creating new regulatory infrastructure precisely as the domestic intoxicating hemp market faces elimination under the December 11 deadline.

The contradiction is stark: federal policy is simultaneously banning domestic intoxicating hemp products while imposing tariffs to restrict foreign competition in cannabinoid imports. Meanwhile, a federal judge in California ruled on October 29 that a Texas marijuana possession conviction from 2019 cannot justify mandatory immigration detention, because Texas law at the time of arrest still included hemp products that federal law had already delisted. The ruling underscores the legal chaos created by misaligned state and federal definitions—a problem Congress is theoretically addressing with new regulations due December 11, but with less than six weeks remaining and no finalized framework, the industry and law enforcement face simultaneous deadlines for compliance with rules that do not yet exist.

October 31, 2026

Massachusetts cannabis regulators are moving to expand medical access across state lines, proposing to allow out-of-state patients diagnosed with debilitating conditions to register for the program regardless of residency. The proposal, introduced at an October 22 commission meeting, would welcome adults 18 and older certified by Massachusetts health professionals into the system—a move that positions the state alongside New Hampshire, Rhode Island, Connecticut, New York, and Maine in reciprocal access agreements. Money Jeremiah MacKinnon, president of the Massachusetts Patient Advocacy Alliance, framed the expansion as essential to stabilizing a struggling medical market: "For the past few years, the medical marijuana market has been struggling, and so to expand the pool of patients that are able to access medical marijuana in the state, I think is a positive thing for the health and long-term stability of the industry." With 41 states now offering medical cannabis, reciprocity has become standard practice—Massachusetts joining the trend signals growing recognition that patient access transcends state borders.

Meanwhile, federal momentum toward descheduling accelerated as a U.S. congressman introduced the "Public Health and Research Reforms in Controlled Substances Act," designed to remove cannabis from Schedule I and overhaul more than 50 years of controlled substance classification policy. Context The bill represents the latest congressional effort to align federal law with a shifting regulatory landscape in which medical cannabis operates legally in 41 states and adult-use programs function in nearly half the country—a structural contradiction that has persisted since Nixon's 1970 Controlled Substances Act, despite his own Shafer Commission recommending decriminalization over five decades ago.

On the science front, conflicting signals emerged about cannabis and sleep. A new University of Colorado Anschutz study challenged the common practice of using cannabis as a sleep aid, suggesting the approach may backfire—a finding that contrasts with widespread patient reports of improved rest. Notable Separately, researchers at the University of Colorado documented cannabis's therapeutic applications in treatment management, advancing clinical understanding of dosing, timing, and condition-specific outcomes. These parallel developments underscore an ongoing pattern in cannabis science: as research expands, nuance replaces blanket claims, revealing that cannabis—like any therapeutic agent—carries context-dependent effects that warrant individual assessment rather than universal recommendations.